Abstract 21
Combining antibiotics with potentiators that increase their activity is a promising strategy to tackle 22 infections caused by antibiotic-resistant and -tolerant bacteria. As these potentiators typically do not 23 interfere with essential processes of bacteria, it has been hypothesized that they are less likely to 24 induce resistance than conventional antibiotics. However, evidence supporting this hypothesis is 25 lacking. In the present study, we investigated whether Burkholderia cenocepacia J2315 biofilms 26 develop resistance towards one such adjuvant, baicalin hydrate (BH), a quorum sensing inhibitor 27 known to increase antibiotic-induced oxidative stress. Biofilms were repeatedly and intermittently 28 treated with tobramycin (TOB) alone or in combination with BH for 24 h. After each cycle of 29 treatment, the remaining cells were quantified using plate counting. After 15 cycles, biofilm cells 30 were less susceptible to treatments with TOB and TOB+BH, compared to the start population, and 31 the potentiating effect of BH towards TOB was lost. Whole genome sequencing was performed to 32 probe which changes were involved in the reduced effect of BH and mutations in 14 protein-coding 33 genes were identified (including mutations in genes involved in central metabolism and in BCAL0296, 34 encoding an ABC transporter), as well as a partial deletion of two larger regions. No changes in the 35 minimal inhibitory or minimal bactericidal concentration of TOB or changes in the number of 36 persister cells were observed in the evolved populations. However, basal intracellular levels of 37 reactive oxygen species (ROS) and ROS levels found after treatment with TOB were markedly 38 decreased in the evolved populations. In addition, in evolved cultures with mutations in BCAL0296, a 39 significantly reduced uptake of TOB was observed. Our results indicate that resistance towards 40 antibiotic-potentiating activity can develop rapidly in B. cenocepacia J2315 biofilms and point to 41 changes in central metabolism, reduced ROS production, and reduced TOB uptake as potential 42 mechanisms. 43 44 45 Importance 46 Bacteria show a markedly reduced susceptibility to antibiotics when growing in a biofilm, which 47 hampers effective treatment of biofilm-related infections. The use of potentiators that increase the 48 activity of antibiotics against biofilms has been proposed as a solution to this problem, but it is 49 unclear whether resistance to these potentiators could develop. Using an experimental evolution 50 approach, we convincingly demonstrate that Burkholderia cenocepacia biofilms rapidly develop 51 resistance towards the tobramycin-potentiating activity of baicalin hydrate. Whole genome 52 sequencing revealed that there are different mechanisms that lead to this resistance, including 53 mutations resulting in metabolic changes, changes in production of intracellular levels of reactive 54 Introduction 60 Due to increasing levels of antimicrobial resistance, novel strategies to tackle bacterial infections are 61 needed and an interesting approach is the use of antibiotic adjuvants or potentiators. Potentiators 62 are compounds with little or no antibacterial activity that interfere with bacterial resistance 63 mechanisms and/or increase antimicrobial activity when co-administered with an antibiotic (1-5). A 64 well-known class of antibiotic adjuvants are quorum sensing (QS) inhibitors (QSIs) (6). QSIs target the 65 cell-density based bacterial communication network that regulates the expression of multiple 66 virulence factors (7, 8) . Whether resistance would develop towards these adjuvants is currently 67 unknown and QSIs have long been accepted as 'evolution-proof': as QSIs do not target pathways 68 essential for growth, it has been hypothesized that development of resistance would not occur (or at 69 least would occur less frequently), due to the lack of selective pressure favouring the rise of resistant 70 mutants (9-13). However, natural selection occurs when heritable variation provides a fitness 71 advantage and QS disruption can affect bacterial fitness in conditions in which a functional QS system 72 is essential (8). This was for example shown by cultivating Pseudomonas aeruginosa in medium with 73 adenosine as a sole carbon source (14) . As growth on adenosine depends on the production of a 74 nucleoside hydrolase, which is positively regulated by the key QS signal receptor LasR, a functional 75 QS system is required for the growth of P. aeruginosa in these conditions (15) . After addition of the 76 brominated furanone C-30 (a known QSI), growth of P. aeruginosa on adenosine was impaired, 77 resulting in selective pressure and the occurrence of resistant mutants. Adding this QSI caused 78 mutations in repressor genes of the multidrug resistance efflux pump MexAB-OrpM, which resulted 79 in an increased resistance towards C-30 (14) . In clinical isolates of cystic fibrosis (CF) patients never 80 exposed to C-30, mutations in the same genes were found, leading to reduced susceptibility to C-30 81 (14, 16) . Based on these results, Maeda et al speculated that any strong selective pressure can induce 82 resistance to antivirulence compounds (14, 17) . In clinical practice, these adjuvants would be co-83 administered with an antibiotic. This means selective pressure imposed by this antibiotic needs to be 84 included in the experimental set up when investigating possible development of resistance towards 85 the adjuvants (1, 2). In addition, while most evolutionary studies on the development of resistance 86 are carried out with planktonic cells (18) (19) (20) , 65-80% of all infections are thought to be biofilm-87 related, and biofilm-associated bacteria typically show a reduced susceptibility towards antimicrobial 88 agents (21). 89
Burkholderia cenocepacia is an opportunistic pathogen that causes severe lung infections in people 90 with CF, which can further develop into a life-threatening systemic infection known as the cepacia 91 syndrome (22) . Antimicrobial therapy in CF often fails due to high innate resistance of B. cenocepacia 92 towards many antibacterial agents and high tolerance associated with its biofilm-lifestyle (22, 23) . 93
Previously, several adjuvants were identified that increased the activity of tobramycin (TOB) (an 94 aminoglycoside antibiotic frequently used in CF lung infections) (24) towards B. cenocepacia biofilms, 95
including the QSI baicalin hydrate (BH) (6, 25) . 96
The goal of the present study is to evaluate whether (and how) B. cenocepacia J2315 biofilm cells can 97 develop resistance towards the TOB-potentiating activity of BH. To this end we used a slightly 98 modified form of a previously-described bead-based biofilm assay (26) in which B. cenocepacia J2315 99 cells were repeatedly and intermittently exposed to TOB, TOB+BH or a control treatment ( Fig. 1) . 100
101

Results and discussion
102
Experimental evolution 103
Three lineages of B. cenocepacia J2315 cells were repeatedly and intermittently exposed to TOB, 104 TOB+BH or a control treatment ( Fig. 1 ). After 24 h of growth on the beads, LIVE/DEAD staining was 105 performed to evaluate biofilm formation ( Fig. S1 ). A dense biofilm was formed in the cavity of the 106 doughnut-shaped bead (rather than on the exterior sides of the bead) with approximately 107 10 7 CFU/bead (prior to treatment). 108
The number of log(CFU/bead) after every cycle is shown in Fig. 2 and Table S1 . After fitting a linear 109 mixed-effect model (LMEM) (using log(CFU/bead) as the dependent variable and cycle, treatment, 110 lineage and their two-and three-way interactions as fixed effects) and plotting the residuals against 111 the corresponding fitted values, no departures from the main assumptions of normality and 112 constancy of error variance were found. The remaining models were fit for each lineage separately 113 following significance of the three way interaction effect and residuals were assessed for each of the 114 models for each lineage. An overview of the statistical results obtained can be found in Tables 1 and  115 S2. 116
At the start of the evolution experiment, cells were more susceptible to the TOB+BH combination 117 than to TOB alone, confirming that BH potentiates the activity of TOB against biofilms, as previously 118
shown (6, 27) . Over time, biofilm-grown B. cenocepacia J2315 cells became gradually less susceptible 119 to the treatment (both to treatment with TOB alone and to the TOB+BH combination treatment); this 120 occurred in all three lineages ( Fig. 2 ). Evolution towards reduced susceptibility occurred significantly 121 faster with the combined TOB+BH treatment, than for the TOB treatment (lineage 1: p = 0.0075; 122 lineage 2 and 3: p < 0.0001) ( Table 1 ) and our data indicate that in all lineages, the TOB-potentiating 123 activity of BH was lost after 15 cycles, i.e. treatment with the combination TOB + BH was not able to 124 kill more cells than treatment with TOB alone (Fig. S2 ). 125 126
Genome analysis 127
To investigate the reason behind this decreased susceptibility, whole genome sequencing was 128 performed. The results are summarised in Table 2 . When considering all (nine) evolved lines, changes 129 in 18 protein-coding genes were observed, as well as a partial deletion of two larger regions. Some 130 changes were common and appeared in all evolved cultures at the same location (e.g. changes in 131 BCAL1315, BCAL1664 and BCAM0949); we speculate these mutations were already present in the 132 start population at low frequency and were enriched for during the experimental evolution. Other 133 changes occurred only in one or a few samples (e.g. mutations in BCAL0929, BCAL2476a, BCAM1901) 134 and likely arose during the evolution study. For several genes that were mutated in multiple evolved 135 cultures we noticed the occurrence of different types of mutations (e.g. BCAL0269, BCAL1525, 136 BCAM0965). 137
All evolved cultures had mutations in the 5' untranslated region (UTR) of BCAL1525 (either a single 138 SNP or insertion of a transposase at variable locations, Table 2 ). BCAL1525 encodes an Flp pilus 139 assembly protein and has a 307 nt long and strongly expressed 5'UTR with multiple transcription 140 start sites (TSS) (28). BCAL1525 to BCAL1536 seem to form an operon with Flp pilus genes, although 141 there is a terminator at position 1690709 to 1690746 between BCAL1525 and BCAL1526, and no 142 further downstream TSS could be identified (28). Flp pili belong to the type IVb pilus family (29), 143 which is poorly characterized in Burkholderia species. In P. aeruginosa type IV pili are thought to play 144 a role in biofilm formation (30), although recent data suggest this may depend on the biofilm model 145 system used (31). Mutations in BCAL1525 occur at high frequency in all evolved cultures, irrespective 146 of the treatment, suggesting there is an evolutionary pressure to lose the pilus function in the given 147 experimental conditions. As biofilm formation is not affected in the course of the experiment, this 148
indicates the Flp pilus is not required for biofilm formation in these conditions. 149 BCAL0296 encodes for both the transmembrane and nucleotide binding domains of an ABC transport 150 protein and it is the only gene which is mutated in all treated evolved populations (except for one 151 evolved population treated with TOB) but not in the control evolved populations; three different 152 types of mutations are observed in this gene (a deletion, a nonsense mutation and a non-153 synonymous substitution, Table 2) . 154
Three mutated genes are related to central metabolism and occur in TOB+BH treated lineages only. 155 BCAL2631 and BCAM0965 are both involved in oxaloacetate production. The mutation in BCAL2631 156 occurs only in one population exposed to TOB+BH; this gene encodes phosphoenol pyruvate kinase, 157 which converts phosphoenol pyruvate to oxaloacetate in the 'reverse TCA cycle'. Its activity typically 158 results in increased oxaloacetate levels and an increased flux through the TCA cycle (32). It was 159 designated as conditionally essential in B. cenocepacia J2315 in a minimal medium with only glucose 160 as substrate (33). BCAM0965 (encoding malate dehydrogenase) is mutated in two out of three 161 evolved populations exposed to TOB+BH. Just like phosphoenol pyruvate kinase, malate 162 dehydrogenase (which converts malate to oxaloacetate) activity will increase cellular oxaloacetate 163 levels, likely stimulating the TCA cycle. BCAM0965 is also conditionally essential in B. cenocepacia 164 J2315 (33). On top of that, in one TOB+BH exposed evolved population, a mutation in a gene 165 encoding the permease of a glucose/mannose ABC transporter (BCAL3040) was observed, likely 166 affecting uptake of certain carbohydrates. 167
None of the mutations observed were located in genes known to be responsible for aminoglycoside 168 resistance such as genes encoding for aminoglycoside-modifying enzymes, efflux pumps, or ribosome 169 methyltransferases, or in genes encoding for ribosomal RNAs (34, 35) . Since mutations in these genes 170 often come at the cost of reduced relative growth fitness (36), the re-growth phase between 171 treatment cycles might have prevented accumulation of such mutations. 172
173
Role of QS and QSI 174 BH was previously described as a QSI (6), and in a recent study we showed it also has QS-175 independent activities, including modulating the oxidative stress response, that potentiate TOB in B. 176 cenocepacia (27). To evaluate whether BH directly inhibits the N-octanoyl-L-homoserine lactone 177 synthase CepI (37, 38), an enzymatic assay with purified CepI was carried out. CepI enzymatic activity 178 was first tested at the concentration of BH slightly below that used for the evolution study (200 µM) 179 and at this concentration BH completely inhibits CepI; subsequently, the IC 50 was determined (46.8 ± 180 6.8 µM) which confirmed that BH inhibits CepI in a concentration dependent way ( Fig. S3 ). 181
The mutation in BCAM1870, coding for CepI, is found in two evolved populations exposed to TOB+BH 182 and in a single population exposed to TOB only; the same mutation (C131W) is found in these three 183 populations. Using qPCR, we investigated the expression of cepI (BCAM1870) and two QS-regulated 184 genes (aidA [BCAS0293] and zmpA [BCAS0409]) (38) in cultures derived from the TOB-exposed 185 biofilm of lineage 2. In stationary phase expression levels of these genes were not altered, but lower 186 expression levels for these genes were observed in late log-phase cultures of the cepI mutant, with 187 remarkably low levels of aidA expression (approx. 60-fold lower expression compared to the control) 188 ( Fig. 3 ). This confirms that QS is indeed affected in this mutant. How the mutation in cepI contributes 189 to an increased fitness of the evolved B. cenocepacia populations is currently unknown. 190 191
Phenotypic characterisation of evolved lines 192
The lack of mutations in known TOB resistance genes suggested that the overall gradual decrease in 193 susceptibility of B. cenocepacia J2315 biofilm cells treated with TOB alone is not caused by a 194 resistance mechanism specific for TOB. This is in line with the MIC and MBC values for TOB obtained 195 for the different lineages ( Persisters are known to occur in B. cenocepacia biofilms (39) and mutations leading to an increased 201 fraction of persisters could (at least partially) explain the reduced effect of TOB+BH in the evolved 202 lineages. However, the fraction of persisters recovered from B. cenocepacia J2315 biofilms after 203 exposure to 4xMIC TOB were low and very similar for the control (0.0224%), the culture evolved in 204 the presence of TOB (0.0393%) and the culture evolved in the presence of TOB+BH (0.0548%), ruling 205 out increased persister formation as a source for the diminishing effect of TOB+BH ( Fig. S4 ). 206
Planktonic growth rate was not affected in any of the lineages evolved in the presence of TOB, but a 207 slightly reduced growth rate was observed for lineages 1 and 2 evolved in the presence of TOB+BH 208 ( Fig. S5 ). This reduction in growth was most pronounced for lineage 2, particularly in early 209 exponential and stationary growth phase. Interestingly, this is also the only lineage that has 210 mutations in two conditionally essential genes (BCAL2631 and BCAM0965) (33), potentially 211 explaining this growth phenotype. 212
Subsequently, we investigated whether there were differences in production of reactive oxygen 213 species (ROS) between the start culture and the evolved populations. We have previously shown that 214 bactericidal antibiotics (including TOB) induce ROS in B. cenocepacia biofilms and that this 215 contributes to the antibiotic-mediated killing in B. cenocepacia (39) (40) (41) . In addition, we have 216 previously shown that BH increases TOB-induced oxidative stress in a QS-independent way (27). ROS 217 are an inevitable by-product of aerobic respiration and as we observed mutations in genes involved 218 in oxaloacetate production (BCAL2631 and BCAM0695) or glucose/mannose transport (BCAL3040) in 219 all lineages treated with TOB+BH (but not in lineages treated with TOB alone or in control lineages, 220
Table 2) we hypothesised these mutations could affect ROS levels. First, we investigated if basal ROS 221 levels (i.e. ROS levels observed in the absence of a treatment with a bactericidal antibiotic) were 222 different between the start culture and the evolved populations. For the control populations and 223 populations treated with TOB, significantly increased basal ROS levels were observed in two and one 224 of the lineages, respectively (Fig. 4A ). For two of the populations that evolved in the presence of 225 TOB+BH, a significant decrease in basal ROS production was observed (p<0.05) (Fig. 4A ). These were 226 also the populations in which mutations in BCAL2631 and/or BCAM0965 (thought to co-regulate TCA 227 activity) were observed. When ROS levels were determined after exposure to TOB, increased ROS 228 production was observed for one of the control populations while no significant difference was 229 observed for any of the populations evolved in the presence of TOB alone (p<0.05) (Fig. 4B ). All 230 populations evolved in the presence of TOB+BH showed reduced ROS levels compared to the start 231 culture after treatment with TOB; this difference was significant (p<0.05) for two lineages (Fig. 4B) . 232
Homologues of the putative ABC transporter BCAL0296, mutated in most evolved treated 233 populations (but not in the controls), have been characterised in other bacteria. In Bradyrhizobium 234 sp. the transporter homologue BclA is involved in protection against stress by antimicrobial peptides 235 (42). BclA has multidrug transport activity and is involved in uptake of peptide-derived/peptide-like 236 compounds, including bleomycin (43). The homologue in Mycobacterium tuberculosis is involved in 237 uptake of vitamin B 12 and bleomycin (44). It is therefore possible that BCAL0296 can import TOB into 238 the cytoplasm under the experimental conditions used. To investigate this, we used a flow cytometry 239 based assay to determine uptake of BODIPY-conjugated TOB. While there are no statistically 240 significant differences when all nine groups (three lineages, three treatments) are compared ( Fig. S6 ), 241 differences in TOB uptake become apparent between treatments when data for the three 242 treatments are averaged over the different lineages (Fig. 6) , with TOB uptake significantly higher in 243 the evolved control lines than in the evolved lines exposed to TOB (p = 0.045) or TOB+BH (p<0.001). 244
No significant difference was observed between the TOB and the TOB+BH exposed cultures. The 245 results from this assay show that there is a significantly higher fraction of the population positive for 246 BODIPY-TOB in evolved cultures without a mutation in BCAL0296 (i.e. the controls), than in evolved 247 cultures with a mutation in BCAL0296 (i.e. the ones exposed to TOB or TOB+BH) (Fig. 5) . These data 248 suggest that BCAL0296 is involved in TOB import in B. cenocepacia and that the mutations occurring 249 after repeated exposure to TOB or TOB+BH contribute to the reduced antimicrobial activity of TOB 250 observed. 251
252
Conclusion
253
In the present study we demonstrate that during experimental evolution in vitro, B. cenocepacia 254 J2315 biofilms gradually but quickly become less susceptible to TOB, and that evolution towards 255 reduced susceptibility occurs significantly faster with the combined TOB+BH treatment. Many 256 genetic changes were observed in the evolved populations exposed to the combination of TOB and 257 BH, and some point to modifications in metabolism as a mechanism underlying the reduced 258 susceptibility. The reduced levels of ROS (both basal levels and levels induced after exposure to TOB) 259 observed in the lineages treated with TOB+BH point in the same direction. In addition, most lineages 260 exposed to TOB or TOB+BH had mutations in BCAL0296, encoding an ABC transporter. Cells from 261 populations in which BCAL0296 was mutated were more likely to accumulate lower levels of TOB 262 intracellularly, providing an additional explanation for the reduced susceptibility of these evolved 263 lineages. Although some genetic changes were found in multiple evolved populations, different 264 lineages exposed to the same treatment appeared to have used different evolutionary trajectories to 265 counteract the potentiating activity of BH. Our results indicate that resistance to potentiators can 266 develop in multiple ways and this might limit their clinical applicability. Finally, our data demonstrate 267 that experimental evolution combined with high-throughput sequencing can indeed identify the 268 genetic changes behind reduced susceptibility, and allows to identify hitherto unknown genes of 269 interest likely involved in B. cenocepacia biofilm resistance and tolerance (45). To evaluate the influence of repeated treatments on biofilm susceptibility, cells were exposed to 300 15 cycles of biofilm formation (24 h), treatment (24 h), and planktonic regrowth (48 h) (Fig. 1) . The 301 planktonic regrowth step was included to generate a sufficiently high number of cells to set up a new 302 biofilm for the next cycle. Biofilms were treated with PS (untreated control), TOB alone (at a 303 concentration of 768 µg/ml which equals 3 times the minimal inhibitory concentration [MIC]), and 304 TOB in combination with BH (250 µM). The concentration of TOB and BH was selected based on 305 preliminary experiments: the concentrations used in the present study lead to a significant reduction 306 in cell numbers compared to the untreated control, but not complete eradication, so that regrowth 307 in the following cycles can occur. Three independent experiments (designated as lineages) were set 308 up for each condition, i.e. TOB (tobramycin), TOB+BH, and an untreated control. The three lineages 309 were started from three different overnight start cultures. Biofilms were grown as described above 310 and after 24 hours the beads were rinsed with PS and treated with TOB or a combination of TOB + 311 BH. After 24 hours of treatment at 37°C, the supernatant was removed, and the beads were rinsed 312 with PS. Each well contained 6 beads: two beads were transferred to Eppendorf tubes containing 8% 313 dimethyl sulfoxide (DMSO; Sigma-Aldrich) in MH for storage at -80°C, while the four remaining beads 314 were transferred to a Falcon tube containing 8 ml MH medium. Sessile cells were detached from the 315 beads by three cycles of vortexing (1 min, Vortex-Genie 2, Scientific Industries Inc., Bohemia, NY, 316 USA) and sonicating (1 min; Branson 3510, Branson Ultrasonics Corp, Danbury, CT, USA). Six ml of 317 this bacterial suspension was transferred to another tube and was incubated for 48 h for regrowth, 318 while shaking at 250 rpm at 37°C (KS 4000i control, IKA Works, Wilmington, NC, USA). The remaining 319 2 ml was used to determine the number of surviving cells per bead (CFU/bead) by plating. 320 321
Determination of the minimal inhibitory concentration (MIC) and minimum bactericidal 322 concentration (MBC) 323
To verify if possible changes in susceptibility over time were due to increased resistance towards 324 TOB, the MIC and MBC for TOB was determined for the start and end population. MICs were 325 determined according to the EUCAST broth microdilution assay using flat-bottom 96-well microtiter 326 plates (MTP; SPL Lifescience, Korea) (46). The MIC was defined as the lowest concentration with a 327 similar optical density as uninoculated growth medium. Absorbance was measured at 590 nm with a 328 multilabel MTP reader (EnVision, Perkin Elmer LAS, Waltham, MA). All MIC determinations were 329 performed in duplicate. The MBC was determined by plating the suspension used for the MIC test 330 and the MBC was the lowest concentration that did not allow recovery of colonies following 48h 331 incubation at 37°C. 332
333
Determination of the number of persisters in tobramycin-exposed B. cenocepacia J2315 biofilms 334
To determine whether the evolutionary changes affected persistence, the number of persisters 335 surviving TOB treatment was compared between biofilms formed by the start and evolved cultures. 336
Biofilms were grown in 96 well microtiter plates as described previously (47) and exposed for 24 h to 337 TOB in a concentration of 4 × MIC (1024 μg/ml) (39). Briefly, an inoculum suspension containing 5 × 338 10 7 CFU/ml was added to the wells of a round bottomed 96 well microtiter plate. Following 4 h of 339 adhesion, the supernatant was removed, and the plates were rinsed with PS. Subsequently, 100 μl of 340 fresh MHB was added, and the plates were further incubated at 37 °C. After 24 h, the supernatant 341 was removed and 120 μl of a TOB solution in PS or 120 μl PS (= control) was added. After 24 h, cells 342 were harvested by vortexing and sonication (2 × 5 min) (Branson 3510, Branson Ultrasonics Corp, 343 Danbury, CT) and quantified by plating on LBA. Ten wells were included per strain, and the 344 experiment was repeated twice. (n = 3). 345 346
Measurement of ROS levels 347
To investigate whether there were differences in the production of reactive oxygen species (ROS) 348 between the start culture and the evolved lineages, ROS was measured in treated and untreated 349 start and evolved cultures. To measure ROS planktonic cultures were exposed to 2',7'-350 dichlorodihydrofluorescein diacetate (H2DCFDA) in a final concentration of 10 μM in LB Broth (40) culture was diluted to an optical density of 0.1 (approximately 10 8 cells/ml). After an additional 24 h 358 of growth in a shaking warm water bath, cell suspensions with an optical density of 1 (approximately 359 10 9 cells/ml) were transferred to falcon tubes and centrifuged for 9 min at 3634 rcf. Cells were 360 resuspended in fresh medium with or without dye to measure ROS. Five wells were included per 361 condition and the experiment was repeated twice (n = 3 x 5). 362 363
Genome sequencing and data analysis 364
After planktonic regrowth of the cells, DNA was extracted using a modified bead-beater protocol, 365 adapted from Mahenthiralingam et al. (48) . RNase-treated DNA was then quantified using the 366 BioDrop μLITE (BioDrop, Cambridge, UK). Genomic DNA from the start culture and all evolved 367 cultures obtained after 15 cycles were sequenced. Libraries were prepared using the NEBNext kit 368 from Illumina, and sequenced either on an Illumina Nextseq 500 or HiSeq 4000, generating 150 bp 369 paired-end reads (Table S3 ). The experimental protocols and the raw sequencing data of all samples 370 can be found in ArrayExpress under the accession number E-MTAB-6236. Sequenced reads were 371 quality trimmed (error probability limit 0.05) and mapped to the B. cenocepacia J2315 reference 372 genome (34) using CLC Genomics Workbench version 11.0.1. (Qiagen, Aarhus, Denmark) with a cut-373 off of 80% for similarity and 50% mapped read length. Mapping parameters were: match score 1, 374 mismatch cost 2, insertion and deletion cost 3. More than 98.6% of reads mapped to the reference 375 genome for all samples (Table S3 ). The un-mapped reads were de-novo assembled in CLC Genomics 376
Workbench, but no contigs with a coverage >10% of the average coverage of the respective sample 377 were found and gene acquisition was therefore excluded. In CLC Genomics Workbench, the InDels 378 and Structural Variants tool was used to detect insertions and deletions, with a p-value threshold of 379 0.0001. The output was manually screened on mapping patterns of un-aligned read ends and only 380 entries with a single breakpoint and identical sequences in the un-aligned read ends were reported. 381
The consensus sequence of the un-aligned read ends was then used to confirm the deletion or to 382 identify the nature of the inserted sequence. A larger insertion sequence cannot be fully deduced in 383 this manner, but only a certain type of transposase which was already present multiple times in the 384 B. cenocepacia J2315 reference genome was detected: Burkholderia cepacia insertion element IS407. 385
Both consensus sequences at insertion breakpoints were consistent with either end of this 386 transposase, it was therefore concluded that the insertion consisted of only that transposase. The 387 Basic Variant Detection tool was used to detect Single Nucleotide Polymorphisms (SNPs) with a 388 minimum coverage of 10 and a reference-to-variant ratio of 35%. This was the lowest cut-off that 389 allowed to clearly distinguish true SNPs from sequencing errors. All SNPs were then manually 390 screened for false positives in regions containing repetitive sequences or hairpins, which caused poor 391 mapping. The function of the genes that acquired mutational changes was determined using the 392 Conserved Domain database (49) and Burkholderia Genome Database (50). 393 394 qPCR 395
Cultures from cycle 15, control lineage 3 and Tob lineage 2, were cultivated in MHB in a shaking 396 incubator at 150 rpm for 6 to 10 hours. Late log phase cultures were harvested at a density of 1 -1.3 397
x 10 9 CFU/ml and stationary phase cultures at a density of 3 -4.5 x 10 9 CFU/ml. Cell pellets were 398 frozen at -80°C and RNA was extracted within one week of harvest, using the RiboPure bacteria kit 399 (Thermo Fisher, Rochester, NY, USA), according to the standard protocol, including DNase treatment. 400
RNA was quantified with the BioDrop μLITE. cDNA was generated with the High Capacity cDNA 401
Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA), from 500 ng of RNA. qPCR was 402 performed in a CFX96 Real-Time System C1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA) using 403 GoTaq qPCR Master Mix (Promega, Madison, WI, USA) . Cq values were normalised against a 404 previously-validated control gene (rpoD, BCAM0918) (51, 52). Fold changes were calculated 405 compared to a standard (mix of all cDNAs in experiment) and log-transformed. Primers are listed in 406 Table S4 . 407 408
Growth curves 409
Growth curves were determined in MHB. 200 µl/well of a 5 x 10 5 CFU/ml inoculum was added in 410
triplicates to a round-bottom MTP and the absorbance at 590 nm was measured in a microplate 411 reader (Envision, Perkin Elmer, Shelton, CT, USA), every 30 minutes for 50 hours. The experiment was 412 repeated 3 times and representative curves are shown. 413 414 Determination of CepI activity in the presence of BH 415 B. cenocepacia CepI was expressed in Escherichia coli BL21(DE3) cells and purified according to the 416 procedure previously described (53). Enzymatic activity was determined by a spectrophotometric 417 assay, according to Christensen et al. (54) , which measures the holo-ACP formation by titrating the 418 release of the free thiol of ACP with dichlorophenylindophenol (DCPIP; = 19100 M -1 cm -1 ). 419
Measurements were performed at 37 °C, in a final volume of 100 μl, using an Eppendorf 420
Biospectrometer. The standard reacion mixture contained 50 mM Hepes pH 7.5, 0.005% Nonidet P-421 40, 0.13 mM DCPIP, 70 μM Octanoyl-ACP (C8-ACP) (55, 56) and 4 μM CepI; the reactions were 422 started by addition of 40 μM S-adenosyl methionine (SAM), after pre-incubation for 10 min. CepI 423 inhibition was initially screened at 200 µM of BH (dissolved in DMSO). CepI inhibition was initially 424 screened at 200 µM (dissolved in DMSO) and subsequently the IC 50 was determined by measuring 425 enzyme activities in presence of different BH concentrations, and fitting data according to equation 426
(1): 427
equation (1) 428 where A [I] is the enzyme activity at BH concentration [I] and A [0] is the enzyme activity without BH. All 429 measurements were performed in triplicate. 430 431
Quantification of intracellular tobramycin levels 432
BODIPY-labelled tobramycin was synthesized as previously described (57). Bacteria were grown 433 under biofilm-forming conditions for 4 h in MHB in the presence of 0.75 µg/mL BODIPY-tobramycin 434 at 37 °C. Following 4 h of biofilm formation, the biofilm was rinsed to remove extracellular 435 tobramycin, homogenized and subjected to flow cytometry analysis (Attune NxT, Life Technologies). 436
The bacterial population was delineated based on the forward and side scatter signal, and a 437 threshold was set to exclude non-cellular particles and cell debris. BODIPY-tobramycin that 438 associated with bacterial cells was determined through excitation with a 488 nm laser. Fluorescence 439 emission was detected through a 530/30 bandpass filter. Controls included bacterial biofilm cells that 440 were not exposed to BODIPY-tobramycin (negative control) or to incremental levels of tobramycin to 441 determine the concentration at which saturation was obtained. Based on the negative control and 442 the concentration of tobramycin where maximal population saturation was obtained, negative and 443 positive flow cytometry gates were determined respectively. At least 10,000 bacteria were analysed 444 per sample. 445
446
Statistical analysis 447
To determine whether the observed variations in survival over time for the different treatments 448 were statistically significant, a linear mixed-effect model (LMEM) was used. The model uses 449 log(CFU/bead) as the dependent variable and cycle, treatment, lineage and their two-and three-way 450 interactions as fixed effects and was fit using SAS version 9.4 (SAS institute, Cary, NC, USA). To 451 account for possible correlations between the measurements over cycles, a compound symmetry 452 variance covariance structure was used. All interaction effects that were not significant were 453 excluded from the model. When an interaction was significant, this was considered as the fixed effect 454 to evaluate differences in treatment effect. Per lineage, treatments were compared pairwise to TOB 455 treatment using the Tukey adjustment method. Assumptions associated with the LMEM were 456 checked based on residuals from the fitted final model (Table S2) . 457
Other data sets were analysed using SPSS version 25 software (SPSS, Chicago, IL, USA). The Wilk test was used to verify the normal distribution assumption of the data. Normally distributed 459 data were analysed using a one-way ANOVA, while non-normally distributed data were analysed with 460 a Kruskal-Wallis 1-way ANOVA. P-values smaller than 0.05 were considered statistically significant. 
